Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

ROGER ALAN GOLDBERG

Allopathic & Osteopathic Physicians Ophthalmology Retina Specialist

NPI
1184866584
CMS profile
368636
Location
WALNUT CREEK, CA

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2019 · Entire year

$110,447.42

109 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2019 · entire year · sorted by reported total

By paying entity

PY2019 · entire year · sorted by reported total

Paying entityAmountRecords
NOVARTIS PHARMACEUTICALS CORPORATION $36,674.81 32
Allergan Inc. $18,107.72 31
Genentech USA, Inc. $15,143.47 15
F. Hoffmann-La Roche AG $11,931.50 7
Carl Zeiss Meditec, Inc. $11,900.97 5
Regeneron Healthcare Solutions, Inc. $9,885.36 6
Genentech, Inc. $4,393.40 4
Alimera Sciences, Inc. $2,374.98 7
Mallinckrodt Enterprises LLC $19.52 1
NotalVision $15.69 1

Page 3 of 3; records 101–109 of 109 matching records. This page contains 9 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

ROGER ALAN GOLDBERG

NPI 1184866584 · CMS profile ID 368636

Allopathic & Osteopathic Physicians / Ophthalmology / Retina Specialist

WALNUT CREEK, CA

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 3 of 3; records 101–109 of 109 matching records. This page contains 9 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1184866584?year=2019&recipient=provider&page=3#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
ROGER ALAN GOLDBERG, NPI 1184866584, CMS profile ID 368636. General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 3 of 3; records 101–109 of 109 matching records. This page contains 9 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1184866584?year=2019&recipient=provider&page=3#records-h. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e.
APA 7
IndustryPayments. (2026). ROGER ALAN GOLDBERG, NPI 1184866584, CMS profile ID 368636. General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 3 of 3; records 101–109 of 109 matching records. This page contains 9 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1184866584?year=2019&recipient=provider&page=3#records-h. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e.
Bluebook
ROGER ALAN GOLDBERG, NPI 1184866584, CMS profile ID 368636, IndustryPayments, General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 3 of 3; records 101–109 of 109 matching records. This page contains 9 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e. https://industrypayments.org/provider/npi-1184866584?year=2019&recipient=provider&page=3#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2019

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2019 · Physicians and non-physician practitioners · CMS publication 2026-06-30

109 matching records · $110,447.42 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 109 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 101–109 of 109.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
NotalVision $15.6902/26/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 624537355 CMS
Genentech USA, Inc. $114.0001/24/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 681193615 CMS
Genentech USA, Inc. $1,280.8501/24/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 681206877 CMS
Genentech USA, Inc. $157.9201/24/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 681209329 CMS
Genentech USA, Inc. $3,300.0001/24/2019 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 681274385 CMS
Genentech USA, Inc. $745.7701/24/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 681280479 CMS
Genentech USA, Inc. $5,280.0001/24/2019 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 681312969 CMS
Genentech USA, Inc. $24.8201/24/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 681320263 CMS
Carl Zeiss Meditec, Inc. $50.9701/22/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 693205629 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $110,447.42 109
PY2020 $77,105.22 52
PY2021 $76,089.87 66
PY2022 $173,333.75 123
PY2023 $175,594.04 152
PY2024 $216,129.82 172
PY2025 $221,358.24 150

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Recipient $3,194.47 6
PY2025 Principal investigator $753,230.25 263
PY2024 Recipient $15,355.81 17
PY2024 Principal investigator $930,895.62 287
PY2023 Recipient $11,243.44 13
PY2023 Principal investigator $1,154,230.86 197
PY2022 Recipient $437.75 1
PY2022 Principal investigator $670,886.79 78
PY2021 Recipient $3,933.94 2
PY2021 Principal investigator $73,571.58 64
PY2020 Recipient $4,061.25 3
PY2020 Principal investigator $190,353.28 66
PY2019 Principal investigator $136,848.52 27

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

269 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 Apellis Pharmaceuticals, Inc. $3,500.00 12/31/2025 Non-covered Recipient Entity
Bay Area Retina Associates
Not supplied No dispute reported 06/30/2026 1250362664
Principal investigator 1 Boehringer Ingelheim International GmbH $40.00 12/31/2025 Non-covered Recipient Entity
Bay Area Retina Associates Walnut Creek
A randomized, double-masked, placebo-controlled trial to evaluate the efficacy, safety and tolerability of oral BI1815368 in participants with center-involved diabetic macular edema No dispute reported 06/30/2026 1220778568
Principal investigator 1 Roche TCRC, Inc. $45,567.00 12/31/2025 Non-covered Recipient Entity
Bay Area Retina
ENTRY INTO HUMAN OF RO7497372 IN PARTICIPANTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1211577551
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $500.00 12/23/2025 Non-covered Recipient Entity
Bay Area Retina Associates Walnut Creek
JADE: Phase II trial in patients with geographic atrophy: A randomized, double-masked, placebo-controlled, dose-finding study to evaluate the efficacy and safety of BI 1584862 No dispute reported 06/30/2026 1220816374
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $30,762.00 12/22/2025 Non-covered Recipient Entity
Bay Area Retina Associates Walnut Creek
A Phase 2 Randomized, double-masked, active-controlled study to evaluate efficacy and safety of two regimens of BI 771716 against pegcetacoplan in patients with geographic atrophy secondary to age-related macular degeneration. No dispute reported 06/30/2026 1220816320
Principal investigator 1 Roche TCRC, Inc. $17,428.00 12/18/2025 Non-covered Recipient Entity
Bay Area Retina
ENTRY INTO HUMAN OF RO7497372 IN PARTICIPANTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1211577560
Principal investigator 1 Apellis Pharmaceuticals, Inc. $258.00 12/17/2025 Non-covered Recipient Entity
Bay Area Retina Associates
A Prospective, Multicenter, Open-Label, Observational Phase 4 Study to Evaluate Real-World Safety, Tolerability, and Treatment Patterns of Pegcetacoplan (Syfovre) in Patients With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1250362654
Principal investigator 1 Boehringer Ingelheim International GmbH $547.50 12/17/2025 Non-covered Recipient Entity
Bay Area Retina Associates Walnut Creek
JADE: Phase II trial in patients with geographic atrophy: A randomized, double-masked, placebo-controlled, dose-finding study to evaluate the efficacy and safety of BI 1584862 No dispute reported 06/30/2026 1220778224
Principal investigator 1 Boehringer Ingelheim International GmbH $15.00 12/17/2025 Non-covered Recipient Entity
Bay Area Retina Associates Walnut Creek
JADE: Phase II trial in patients with geographic atrophy: A randomized, double-masked, placebo-controlled, dose-finding study to evaluate the efficacy and safety of BI 1584862 No dispute reported 06/30/2026 1220778226
Principal investigator 1 Genentech, Inc. $1,867.00 12/17/2025 Non-covered Recipient Entity
BAY AREA RETINA ASSOCIATES A M
PH III STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ASTEGOLIMAB IN COPD No dispute reported 06/30/2026 1211577576
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $703.00 12/11/2025 Non-covered Recipient Entity
Bay Area Retina Associates Walnut Creek
A Phase 2 Randomized, double-masked, active-controlled study to evaluate efficacy and safety of two regimens of BI 771716 against pegcetacoplan in patients with geographic atrophy secondary to age-related macular degeneration. No dispute reported 06/30/2026 1220816318
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $24,883.00 12/11/2025 Non-covered Recipient Entity
Bay Area Retina Associates Walnut Creek
JADE: Phase II trial in patients with geographic atrophy: A randomized, double-masked, placebo-controlled, dose-finding study to evaluate the efficacy and safety of BI 1584862 No dispute reported 06/30/2026 1220816368
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $750.00 12/11/2025 Non-covered Recipient Entity
Bay Area Retina Associates Walnut Creek
JADE: Phase II trial in patients with geographic atrophy: A randomized, double-masked, placebo-controlled, dose-finding study to evaluate the efficacy and safety of BI 1584862 No dispute reported 06/30/2026 1220816370
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $750.00 12/11/2025 Non-covered Recipient Entity
Bay Area Retina Associates Walnut Creek
JADE: Phase II trial in patients with geographic atrophy: A randomized, double-masked, placebo-controlled, dose-finding study to evaluate the efficacy and safety of BI 1584862 No dispute reported 06/30/2026 1220816372
Principal investigator 1 Genentech, Inc. $500.00 12/10/2025 Non-covered Recipient Entity
BAY AREA RETINA ASSOCIATES A M
PH III STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ASTEGOLIMAB IN COPD No dispute reported 06/30/2026 1211577568
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $491.00 12/05/2025 Non-covered Recipient Entity
Bay Area Retina Associates Walnut Creek
A Phase 2 Randomized, double-masked, active-controlled study to evaluate efficacy and safety of two regimens of BI 771716 against pegcetacoplan in patients with geographic atrophy secondary to age-related macular degeneration. No dispute reported 06/30/2026 1220816314
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $750.00 12/05/2025 Non-covered Recipient Entity
Bay Area Retina Associates Walnut Creek
A Phase 2 Randomized, double-masked, active-controlled study to evaluate efficacy and safety of two regimens of BI 771716 against pegcetacoplan in patients with geographic atrophy secondary to age-related macular degeneration. No dispute reported 06/30/2026 1220816316
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $514.00 12/05/2025 Non-covered Recipient Entity
Bay Area Retina Associates Walnut Creek
JADE: Phase II trial in patients with geographic atrophy: A randomized, double-masked, placebo-controlled, dose-finding study to evaluate the efficacy and safety of BI 1584862 No dispute reported 06/30/2026 1220816366
Principal investigator 1 Genentech, Inc. $40.00 12/05/2025 Non-covered Recipient Entity
BAY AREA RETINA ASSOCIATES A M
PH III STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ASTEGOLIMAB IN COPD No dispute reported 06/30/2026 1211577573
Principal investigator 1 Boehringer Ingelheim International GmbH $47.50 12/01/2025 Non-covered Recipient Entity
Bay Area Retina Associates Walnut Creek
A Phase 2 Randomized, double-masked, active-controlled study to evaluate efficacy and safety of two regimens of BI 771716 against pegcetacoplan in patients with geographic atrophy secondary to age-related macular degeneration. No dispute reported 06/30/2026 1220778180
Principal investigator 1 Boehringer Ingelheim International GmbH $43.00 12/01/2025 Non-covered Recipient Entity
Bay Area Retina Associates Walnut Creek
JADE: Phase II trial in patients with geographic atrophy: A randomized, double-masked, placebo-controlled, dose-finding study to evaluate the efficacy and safety of BI 1584862 No dispute reported 06/30/2026 1220778218
Principal investigator 1 Boehringer Ingelheim International GmbH $24.94 12/01/2025 Non-covered Recipient Entity
Bay Area Retina Associates Walnut Creek
JADE: Phase II trial in patients with geographic atrophy: A randomized, double-masked, placebo-controlled, dose-finding study to evaluate the efficacy and safety of BI 1584862 No dispute reported 06/30/2026 1220778220
Principal investigator 1 Apellis Pharmaceuticals, Inc. $750.00 11/21/2025 Non-covered Recipient Entity
Bay Area Retina Associates
Not supplied No dispute reported 06/30/2026 1250362662
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $417.12 11/17/2025 Non-covered Recipient Entity
Bay Area Retina Associates Walnut Creek
JADE: Phase II trial in patients with geographic atrophy: A randomized, double-masked, placebo-controlled, dose-finding study to evaluate the efficacy and safety of BI 1584862 No dispute reported 06/30/2026 1220816364
Principal investigator 1 Apellis Pharmaceuticals, Inc. $750.00 11/14/2025 Non-covered Recipient Entity
Bay Area Retina Associates
Not supplied No dispute reported 06/30/2026 1250362660
Principal investigator 1 Genentech, Inc. $46.22 11/14/2025 Non-covered Recipient Entity
BAY AREA RETINA ASSOCIATES A MEDICAL GROUP
iAMD Observational Study No dispute reported 06/30/2026 1211577733
Principal investigator 1 Neurotech Pharmaceuticals, Inc. $300.00 11/11/2025 Non-covered Recipient Entity
Bay Area Retina Associates
NTMT-03C No dispute reported 06/30/2026 1249334387
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $150.49 11/10/2025 Non-covered Recipient Entity
Bay Area Retina Associates Walnut Creek
A Phase 2 Randomized, double-masked, active-controlled study to evaluate efficacy and safety of two regimens of BI 771716 against pegcetacoplan in patients with geographic atrophy secondary to age-related macular degeneration. No dispute reported 06/30/2026 1220816312
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $37,697.00 11/10/2025 Non-covered Recipient Entity
Bay Area Retina Associates Walnut Creek
JADE: Phase II trial in patients with geographic atrophy: A randomized, double-masked, placebo-controlled, dose-finding study to evaluate the efficacy and safety of BI 1584862 No dispute reported 06/30/2026 1220816362
Principal investigator 1 Genentech, Inc. $500.00 11/07/2025 Non-covered Recipient Entity
BAY AREA RETINA ASSOCIATES A MEDICAL GROUP
iAMD Observational Study No dispute reported 06/30/2026 1211577741
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $450.00 11/05/2025 Non-covered Recipient Entity
Bay Area Retina Associates Walnut Creek
A Phase 2 Randomized, double-masked, active-controlled study to evaluate efficacy and safety of two regimens of BI 771716 against pegcetacoplan in patients with geographic atrophy secondary to age-related macular degeneration. No dispute reported 06/30/2026 1220816310
Principal investigator 1 Genentech, Inc. $1,437.00 11/05/2025 Non-covered Recipient Entity
BAY AREA RETINA ASSOCIATES A MEDICAL GROUP
iAMD Observational Study No dispute reported 06/30/2026 1211577738
Principal investigator 1 Genentech, Inc. $6,300.00 11/05/2025 Non-covered Recipient Entity
BAY AREA RETINA ASSOCIATES A MEDICAL GROUP
iAMD Observational Study No dispute reported 06/30/2026 1211577745
Principal investigator 1 Boehringer Ingelheim International GmbH $47.50 11/01/2025 Non-covered Recipient Entity
Bay Area Retina Associates Walnut Creek
A Phase 2 Randomized, double-masked, active-controlled study to evaluate efficacy and safety of two regimens of BI 771716 against pegcetacoplan in patients with geographic atrophy secondary to age-related macular degeneration. No dispute reported 06/30/2026 1220778178
Principal investigator 1 Boehringer Ingelheim International GmbH $40.00 10/31/2025 Non-covered Recipient Entity
Bay Area Retina Associates Walnut Creek
A randomized, double-masked, placebo-controlled trial to evaluate the efficacy, safety and tolerability of oral BI1815368 in participants with center-involved diabetic macular edema No dispute reported 06/30/2026 1220778564
Principal investigator 1 Janssen Research & Development, LLC $48.00 10/30/2025 Non-covered Recipient Entity
BAY AREA RETINA ASSOCIATES
Long-term Extension Study for Participants with Geographic Atrophy (GA) Secondary to Age-related Macular Degeneration (AMD) in JNJ-81201887 Parent Clinical Studies No dispute reported 06/30/2026 1175437651
Principal investigator 1 Boehringer Ingelheim International GmbH $40.00 10/28/2025 Non-covered Recipient Entity
Bay Area Retina Associates Walnut Creek
A randomized, double-masked, placebo-controlled trial to evaluate the efficacy, safety and tolerability of oral BI1815368 in participants with center-involved diabetic macular edema No dispute reported 06/30/2026 1220778566
Principal investigator 1 Roche TCRC, Inc. $3,993.00 10/28/2025 Non-covered Recipient Entity
Bay Area Retina
ENTRY INTO HUMAN OF RO7497372 IN PARTICIPANTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1211577548
Principal investigator 1 Boehringer Ingelheim International GmbH $99.90 10/27/2025 Non-covered Recipient Entity
Bay Area Retina Associates Walnut Creek
JADE: Phase II trial in patients with geographic atrophy: A randomized, double-masked, placebo-controlled, dose-finding study to evaluate the efficacy and safety of BI 1584862 No dispute reported 06/30/2026 1220778222
Principal investigator 1 Apellis Pharmaceuticals, Inc. $123.00 10/24/2025 Non-covered Recipient Entity
Bay Area Retina Associates
A Prospective, Multicenter, Open-Label, Observational Phase 4 Study to Evaluate Real-World Safety, Tolerability, and Treatment Patterns of Pegcetacoplan (Syfovre) in Patients With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1250362658
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $194.00 10/21/2025 Non-covered Recipient Entity
Bay Area Retina Associates Walnut Creek
JADE: Phase II trial in patients with geographic atrophy: A randomized, double-masked, placebo-controlled, dose-finding study to evaluate the efficacy and safety of BI 1584862 No dispute reported 06/30/2026 1220816358
Principal investigator 1 Apellis Pharmaceuticals, Inc. $500.00 10/20/2025 Non-covered Recipient Entity
Bay Area Retina Associates
A Prospective, Multicenter, Open-Label, Observational Phase 4 Study to Evaluate Real-World Safety, Tolerability, and Treatment Patterns of Pegcetacoplan (Syfovre) in Patients With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1250362656
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $750.00 10/20/2025 Non-covered Recipient Entity
Bay Area Retina Associates Walnut Creek
JADE: Phase II trial in patients with geographic atrophy: A randomized, double-masked, placebo-controlled, dose-finding study to evaluate the efficacy and safety of BI 1584862 No dispute reported 06/30/2026 1220816360
Principal investigator 1 Neurotech Pharmaceuticals, Inc. $2,300.00 10/20/2025 Non-covered Recipient Entity
Bay Area Retina Associates
NTMT-03C No dispute reported 06/30/2026 1249334385
Principal investigator 1 Genentech, Inc. $500.00 10/17/2025 Non-covered Recipient Entity
BAY AREA RETINA ASSOCIATES A MEDICAL GROUP
iAMD Observational Study No dispute reported 06/30/2026 1211577729
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $188.50 10/15/2025 Non-covered Recipient Entity
Bay Area Retina Associates Walnut Creek
A Phase 2 Randomized, double-masked, active-controlled study to evaluate efficacy and safety of two regimens of BI 771716 against pegcetacoplan in patients with geographic atrophy secondary to age-related macular degeneration. No dispute reported 06/30/2026 1220816308
Principal investigator 1 Roche TCRC, Inc. $500.00 10/15/2025 Non-covered Recipient Entity
Bay Area Retina
ENTRY INTO HUMAN OF RO7497372 IN PARTICIPANTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1211577564
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $6,016.40 10/13/2025 Non-covered Recipient Entity
Bay Area Retina Associates Walnut Creek
A Phase 2 Randomized, double-masked, active-controlled study to evaluate efficacy and safety of two regimens of BI 771716 against pegcetacoplan in patients with geographic atrophy secondary to age-related macular degeneration. No dispute reported 06/30/2026 1220816298
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $34,509.00 10/10/2025 Non-covered Recipient Entity
Bay Area Retina Associates Walnut Creek
A Phase 2 Randomized, double-masked, active-controlled study to evaluate efficacy and safety of two regimens of BI 771716 against pegcetacoplan in patients with geographic atrophy secondary to age-related macular degeneration. No dispute reported 06/30/2026 1220816296
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $84,984.00 10/09/2025 Non-covered Recipient Entity
Bay Area Retina Associates Walnut Creek
JADE: Phase II trial in patients with geographic atrophy: A randomized, double-masked, placebo-controlled, dose-finding study to evaluate the efficacy and safety of BI 1584862 No dispute reported 06/30/2026 1220816352
Principal investigator 1 Neurotech Pharmaceuticals, Inc. $1,156.60 10/03/2025 Non-covered Recipient Entity
Bay Area Retina Associates
NTMT-03C No dispute reported 06/30/2026 1249334353
Principal investigator 1 Roche TCRC, Inc. $10,024.00 10/03/2025 Non-covered Recipient Entity
Bay Area Retina
ENTRY INTO HUMAN OF RO7497372 IN PARTICIPANTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1211577556
Principal investigator 1 Boehringer Ingelheim International GmbH $47.50 10/01/2025 Non-covered Recipient Entity
Bay Area Retina Associates Walnut Creek
A Phase 2 Randomized, double-masked, active-controlled study to evaluate efficacy and safety of two regimens of BI 771716 against pegcetacoplan in patients with geographic atrophy secondary to age-related macular degeneration. No dispute reported 06/30/2026 1220778176
Principal investigator 1 Boehringer Ingelheim International GmbH $43.00 10/01/2025 Non-covered Recipient Entity
Bay Area Retina Associates Walnut Creek
JADE: Phase II trial in patients with geographic atrophy: A randomized, double-masked, placebo-controlled, dose-finding study to evaluate the efficacy and safety of BI 1584862 No dispute reported 06/30/2026 1220778216
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $16,642.00 10/01/2025 Non-covered Recipient Entity
Bay Area Retina Associates Walnut Creek
A Phase 2 Randomized, double-masked, active-controlled study to evaluate efficacy and safety of two regimens of BI 771716 against pegcetacoplan in patients with geographic atrophy secondary to age-related macular degeneration. No dispute reported 06/30/2026 1220816306
Principal investigator 1 Boehringer Ingelheim International GmbH $40.00 09/30/2025 Non-covered Recipient Entity
Bay Area Retina Associates Walnut Creek
A randomized, double-masked, placebo-controlled trial to evaluate the efficacy, safety and tolerability of oral BI1815368 in participants with center-involved diabetic macular edema No dispute reported 06/30/2026 1220778554
Principal investigator 1 Roche TCRC, Inc. $4,245.00 09/30/2025 Non-covered Recipient Entity
Bay Area Retina
ENTRY INTO HUMAN OF RO7497372 IN PARTICIPANTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1211577540
Principal investigator 1 Apellis Pharmaceuticals, Inc. $15,503.60 09/26/2025 Non-covered Recipient Entity
Bay Area Retina Associates
An Extension Study to Evaluate the Long-term Safety and Efficacy of Pegcetacoplan (APL-2) in Subjects With Geographic Atrophy Secondary to AMD No dispute reported 06/30/2026 1250362652
Principal investigator 1 Boehringer Ingelheim International GmbH $559.44 09/24/2025 Non-covered Recipient Entity
Bay Area Retina Associates Walnut Creek
JADE: Phase II trial in patients with geographic atrophy: A randomized, double-masked, placebo-controlled, dose-finding study to evaluate the efficacy and safety of BI 1584862 No dispute reported 06/30/2026 1220778210
Principal investigator 1 Boehringer Ingelheim International GmbH $1,022.00 09/24/2025 Non-covered Recipient Entity
Bay Area Retina Associates Walnut Creek
JADE: Phase II trial in patients with geographic atrophy: A randomized, double-masked, placebo-controlled, dose-finding study to evaluate the efficacy and safety of BI 1584862 No dispute reported 06/30/2026 1220778212
Principal investigator 1 Boehringer Ingelheim International GmbH $28.00 09/24/2025 Non-covered Recipient Entity
Bay Area Retina Associates Walnut Creek
JADE: Phase II trial in patients with geographic atrophy: A randomized, double-masked, placebo-controlled, dose-finding study to evaluate the efficacy and safety of BI 1584862 No dispute reported 06/30/2026 1220778214
Principal investigator 1 Boehringer Ingelheim International GmbH $139.92 09/24/2025 Non-covered Recipient Entity
Bay Area Retina Associates Walnut Creek
A randomized, double-masked, placebo-controlled trial to evaluate the efficacy, safety and tolerability of oral BI1815368 in participants with center-involved diabetic macular edema No dispute reported 06/30/2026 1220778556
Principal investigator 1 Boehringer Ingelheim International GmbH $199.80 09/24/2025 Non-covered Recipient Entity
Bay Area Retina Associates Walnut Creek
A randomized, double-masked, placebo-controlled trial to evaluate the efficacy, safety and tolerability of oral BI1815368 in participants with center-involved diabetic macular edema No dispute reported 06/30/2026 1220778558
Principal investigator 1 Boehringer Ingelheim International GmbH $146.00 09/24/2025 Non-covered Recipient Entity
Bay Area Retina Associates Walnut Creek
A randomized, double-masked, placebo-controlled trial to evaluate the efficacy, safety and tolerability of oral BI1815368 in participants with center-involved diabetic macular edema No dispute reported 06/30/2026 1220778560
Principal investigator 1 Boehringer Ingelheim International GmbH $43.70 09/24/2025 Non-covered Recipient Entity
Bay Area Retina Associates Walnut Creek
A randomized, double-masked, placebo-controlled trial to evaluate the efficacy, safety and tolerability of oral BI1815368 in participants with center-involved diabetic macular edema No dispute reported 06/30/2026 1220778562
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $126.86 09/23/2025 Non-covered Recipient Entity
Bay Area Retina Associates Walnut Creek
A Phase 2 Randomized, double-masked, active-controlled study to evaluate efficacy and safety of two regimens of BI 771716 against pegcetacoplan in patients with geographic atrophy secondary to age-related macular degeneration. No dispute reported 06/30/2026 1220816304
Principal investigator 1 Roche TCRC, Inc. $500.00 09/22/2025 Non-covered Recipient Entity
Bay Area Retina
ENTRY INTO HUMAN OF RO7497372 IN PARTICIPANTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1211577537
Principal investigator 1 Genentech, Inc. $18.50 09/17/2025 Non-covered Recipient Entity
BAY AREA RETINA ASSOCIATES A MEDICAL GROUP
iAMD Observational Study No dispute reported 06/30/2026 1211577697
Principal investigator 1 Roche TCRC, Inc. $5,489.00 09/15/2025 Non-covered Recipient Entity
Bay Area Retina
ENTRY INTO HUMAN OF RO7497372 IN PARTICIPANTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1211577544
Principal investigator 1 Genentech, Inc. $3,304.00 09/12/2025 Non-covered Recipient Entity
BAY AREA RETINA ASSOCIATES A MEDICAL GROUP
iAMD Observational Study No dispute reported 06/30/2026 1211577670
Principal investigator 1 Genentech, Inc. $500.00 09/12/2025 Non-covered Recipient Entity
BAY AREA RETINA ASSOCIATES A MEDICAL GROUP
iAMD Observational Study No dispute reported 06/30/2026 1211577686
Principal investigator 1 Genentech, Inc. $84.00 09/12/2025 Non-covered Recipient Entity
BAY AREA RETINA ASSOCIATES A MEDICAL GROUP
iAMD Observational Study No dispute reported 06/30/2026 1211577705
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $500.00 09/08/2025 Non-covered Recipient Entity
Bay Area Retina Associates Walnut Creek
JADE: Phase II trial in patients with geographic atrophy: A randomized, double-masked, placebo-controlled, dose-finding study to evaluate the efficacy and safety of BI 1584862 No dispute reported 06/30/2026 1220816346
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $194.00 09/08/2025 Non-covered Recipient Entity
Bay Area Retina Associates Walnut Creek
JADE: Phase II trial in patients with geographic atrophy: A randomized, double-masked, placebo-controlled, dose-finding study to evaluate the efficacy and safety of BI 1584862 No dispute reported 06/30/2026 1220816348
Principal investigator 1 Apellis Pharmaceuticals, Inc. $1,000.00 09/05/2025 Non-covered Recipient Entity
Bay Area Retina Associates
A Phase 2, Randomized, Placebo Controlled, Multicenter, Masked Study to Evaluate the Efficacy, Safety, Tolerability, and Pharmacodynamics of Multidose APL 3007 in Combination With Syfovre/Pegcetacoplan (APL-2) in Patients Diagnosed With Geographic Atrophy Secondary to Age Related Macular Degeneratio No dispute reported 06/30/2026 1250362564
Principal investigator 1 Apellis Pharmaceuticals, Inc. $14,500.00 09/05/2025 Non-covered Recipient Entity
Bay Area Retina Associates
A Phase 2, Randomized, Placebo Controlled, Multicenter, Masked Study to Evaluate the Efficacy, Safety, Tolerability, and Pharmacodynamics of Multidose APL 3007 in Combination With Syfovre/Pegcetacoplan (APL-2) in Patients Diagnosed With Geographic Atrophy Secondary to Age Related Macular Degeneratio No dispute reported 06/30/2026 1250362566
Recipient Regeneron Pharmaceuticals, Inc. $1,135.83 09/05/2025 Covered Recipient Physician A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1184117817
Principal investigator 1 Boehringer Ingelheim International GmbH $25.00 09/03/2025 Non-covered Recipient Entity
Bay Area Retina Associates Walnut Creek
A randomized, double-masked, placebo-controlled trial to evaluate the efficacy, safety and tolerability of oral BI1815368 in participants with center-involved diabetic macular edema No dispute reported 06/30/2026 1220778550
Principal investigator 1 Boehringer Ingelheim International GmbH $95.01 09/03/2025 Non-covered Recipient Entity
Bay Area Retina Associates Walnut Creek
A randomized, double-masked, placebo-controlled trial to evaluate the efficacy, safety and tolerability of oral BI1815368 in participants with center-involved diabetic macular edema No dispute reported 06/30/2026 1220778552
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $750.00 09/03/2025 Non-covered Recipient Entity
Bay Area Retina Associates Walnut Creek
A Phase 2 Randomized, double-masked, active-controlled study to evaluate efficacy and safety of two regimens of BI 771716 against pegcetacoplan in patients with geographic atrophy secondary to age-related macular degeneration. No dispute reported 06/30/2026 1220816300
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $750.00 09/03/2025 Non-covered Recipient Entity
Bay Area Retina Associates Walnut Creek
A Phase 2 Randomized, double-masked, active-controlled study to evaluate efficacy and safety of two regimens of BI 771716 against pegcetacoplan in patients with geographic atrophy secondary to age-related macular degeneration. No dispute reported 06/30/2026 1220816302
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $750.00 09/03/2025 Non-covered Recipient Entity
Bay Area Retina Associates Walnut Creek
JADE: Phase II trial in patients with geographic atrophy: A randomized, double-masked, placebo-controlled, dose-finding study to evaluate the efficacy and safety of BI 1584862 No dispute reported 06/30/2026 1220816354
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $500.00 09/03/2025 Non-covered Recipient Entity
Bay Area Retina Associates Walnut Creek
JADE: Phase II trial in patients with geographic atrophy: A randomized, double-masked, placebo-controlled, dose-finding study to evaluate the efficacy and safety of BI 1584862 No dispute reported 06/30/2026 1220816356
Principal investigator 1 Genentech, Inc. $44.25 09/02/2025 Non-covered Recipient Entity
BAY AREA RETINA ASSOCIATES A MEDICAL GROUP
A Phase 1 SAD MD in Diabetic Macular Edema No dispute reported 06/30/2026 1211577701
Principal investigator 1 Genentech, Inc. $1,867.00 09/02/2025 Non-covered Recipient Entity
BAY AREA RETINA ASSOCIATES A MEDICAL GROUP
iAMD Observational Study No dispute reported 06/30/2026 1211577717
Principal investigator 1 Genentech, Inc. $20.67 09/02/2025 Non-covered Recipient Entity
BAY AREA RETINA ASSOCIATES A MEDICAL GROUP
A Phase 1 SAD MD in Diabetic Macular Edema No dispute reported 06/30/2026 1211577725
Principal investigator 1 Boehringer Ingelheim International GmbH $47.50 09/01/2025 Non-covered Recipient Entity
Bay Area Retina Associates Walnut Creek
A Phase 2 Randomized, double-masked, active-controlled study to evaluate efficacy and safety of two regimens of BI 771716 against pegcetacoplan in patients with geographic atrophy secondary to age-related macular degeneration. No dispute reported 06/30/2026 1220778170
Principal investigator 1 Boehringer Ingelheim International GmbH $43.00 09/01/2025 Non-covered Recipient Entity
Bay Area Retina Associates Walnut Creek
JADE: Phase II trial in patients with geographic atrophy: A randomized, double-masked, placebo-controlled, dose-finding study to evaluate the efficacy and safety of BI 1584862 No dispute reported 06/30/2026 1220778202
Recipient F. Hoffmann-La Roche AG $439.58 08/29/2025 Covered Recipient Physician VA2 PhIII Yosemite No dispute reported 06/30/2026 1211538661
Principal investigator 1 Boehringer Ingelheim International GmbH $511.00 08/26/2025 Non-covered Recipient Entity
Bay Area Retina Associates Walnut Creek
A Phase 2 Randomized, double-masked, active-controlled study to evaluate efficacy and safety of two regimens of BI 771716 against pegcetacoplan in patients with geographic atrophy secondary to age-related macular degeneration. No dispute reported 06/30/2026 1220778172
Principal investigator 1 Boehringer Ingelheim International GmbH $97.44 08/26/2025 Non-covered Recipient Entity
Bay Area Retina Associates Walnut Creek
A Phase 2 Randomized, double-masked, active-controlled study to evaluate efficacy and safety of two regimens of BI 771716 against pegcetacoplan in patients with geographic atrophy secondary to age-related macular degeneration. No dispute reported 06/30/2026 1220778174
Principal investigator 1 Boehringer Ingelheim International GmbH $119.88 08/26/2025 Non-covered Recipient Entity
Bay Area Retina Associates Walnut Creek
JADE: Phase II trial in patients with geographic atrophy: A randomized, double-masked, placebo-controlled, dose-finding study to evaluate the efficacy and safety of BI 1584862 No dispute reported 06/30/2026 1220778204
Principal investigator 1 Boehringer Ingelheim International GmbH $146.00 08/26/2025 Non-covered Recipient Entity
Bay Area Retina Associates Walnut Creek
JADE: Phase II trial in patients with geographic atrophy: A randomized, double-masked, placebo-controlled, dose-finding study to evaluate the efficacy and safety of BI 1584862 No dispute reported 06/30/2026 1220778206
Principal investigator 1 Boehringer Ingelheim International GmbH $4.00 08/26/2025 Non-covered Recipient Entity
Bay Area Retina Associates Walnut Creek
JADE: Phase II trial in patients with geographic atrophy: A randomized, double-masked, placebo-controlled, dose-finding study to evaluate the efficacy and safety of BI 1584862 No dispute reported 06/30/2026 1220778208
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $750.00 08/25/2025 Non-covered Recipient Entity
Bay Area Retina Associates Walnut Creek
JADE: Phase II trial in patients with geographic atrophy: A randomized, double-masked, placebo-controlled, dose-finding study to evaluate the efficacy and safety of BI 1584862 No dispute reported 06/30/2026 1220816350
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $254.00 08/20/2025 Non-covered Recipient Entity
Bay Area Retina Associates Walnut Creek
JADE: Phase II trial in patients with geographic atrophy: A randomized, double-masked, placebo-controlled, dose-finding study to evaluate the efficacy and safety of BI 1584862 No dispute reported 06/30/2026 1220816324
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $73.92 08/20/2025 Non-covered Recipient Entity
Bay Area Retina Associates Walnut Creek
JADE: Phase II trial in patients with geographic atrophy: A randomized, double-masked, placebo-controlled, dose-finding study to evaluate the efficacy and safety of BI 1584862 No dispute reported 06/30/2026 1220816326
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $149.00 08/19/2025 Non-covered Recipient Entity
Bay Area Retina Associates Walnut Creek
A Phase 2 Randomized, double-masked, active-controlled study to evaluate efficacy and safety of two regimens of BI 771716 against pegcetacoplan in patients with geographic atrophy secondary to age-related macular degeneration. No dispute reported 06/30/2026 1220816292
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $70.91 08/19/2025 Non-covered Recipient Entity
Bay Area Retina Associates Walnut Creek
JADE: Phase II trial in patients with geographic atrophy: A randomized, double-masked, placebo-controlled, dose-finding study to evaluate the efficacy and safety of BI 1584862 No dispute reported 06/30/2026 1220816340
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $697.00 08/19/2025 Non-covered Recipient Entity
Bay Area Retina Associates Walnut Creek
JADE: Phase II trial in patients with geographic atrophy: A randomized, double-masked, placebo-controlled, dose-finding study to evaluate the efficacy and safety of BI 1584862 No dispute reported 06/30/2026 1220816342
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $29.77 08/19/2025 Non-covered Recipient Entity
Bay Area Retina Associates Walnut Creek
JADE: Phase II trial in patients with geographic atrophy: A randomized, double-masked, placebo-controlled, dose-finding study to evaluate the efficacy and safety of BI 1584862 No dispute reported 06/30/2026 1220816344
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $89,640.00 08/18/2025 Non-covered Recipient Entity
Bay Area Retina Associates Walnut Creek
A Phase 2 Randomized, double-masked, active-controlled study to evaluate efficacy and safety of two regimens of BI 771716 against pegcetacoplan in patients with geographic atrophy secondary to age-related macular degeneration. No dispute reported 06/30/2026 1220816294
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $83.46 08/15/2025 Non-covered Recipient Entity
Bay Area Retina Associates Walnut Creek
JADE: Phase II trial in patients with geographic atrophy: A randomized, double-masked, placebo-controlled, dose-finding study to evaluate the efficacy and safety of BI 1584862 No dispute reported 06/30/2026 1220816338
Principal investigator 1 Genentech, Inc. $3,699.00 08/14/2025 Non-covered Recipient Entity
BAY AREA RETINA ASSOCIATES A MEDICAL GROUP
A Phase 1 SAD MD in Diabetic Macular Edema No dispute reported 06/30/2026 1211577713
Principal investigator 1 Genentech, Inc. $3,203.00 08/14/2025 Non-covered Recipient Entity
BAY AREA RETINA ASSOCIATES A MEDICAL GROUP
A Phase 1 SAD MD in Diabetic Macular Edema No dispute reported 06/30/2026 1211577720
Principal investigator 1 Genentech, Inc. $316.00 08/12/2025 Non-covered Recipient Entity
BAY AREA RETINA ASSOCIATES A MEDICAL GROUP
A Phase 1 SAD MD in Diabetic Macular Edema No dispute reported 06/30/2026 1211577694
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $500.00 08/11/2025 Non-covered Recipient Entity
Bay Area Retina Associates Walnut Creek
JADE: Phase II trial in patients with geographic atrophy: A randomized, double-masked, placebo-controlled, dose-finding study to evaluate the efficacy and safety of BI 1584862 No dispute reported 06/30/2026 1220816328
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $760.00 08/11/2025 Non-covered Recipient Entity
Bay Area Retina Associates Walnut Creek
JADE: Phase II trial in patients with geographic atrophy: A randomized, double-masked, placebo-controlled, dose-finding study to evaluate the efficacy and safety of BI 1584862 No dispute reported 06/30/2026 1220816330
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $750.00 08/11/2025 Non-covered Recipient Entity
Bay Area Retina Associates Walnut Creek
JADE: Phase II trial in patients with geographic atrophy: A randomized, double-masked, placebo-controlled, dose-finding study to evaluate the efficacy and safety of BI 1584862 No dispute reported 06/30/2026 1220816332
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $750.00 08/11/2025 Non-covered Recipient Entity
Bay Area Retina Associates Walnut Creek
JADE: Phase II trial in patients with geographic atrophy: A randomized, double-masked, placebo-controlled, dose-finding study to evaluate the efficacy and safety of BI 1584862 No dispute reported 06/30/2026 1220816334
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $750.00 08/11/2025 Non-covered Recipient Entity
Bay Area Retina Associates Walnut Creek
JADE: Phase II trial in patients with geographic atrophy: A randomized, double-masked, placebo-controlled, dose-finding study to evaluate the efficacy and safety of BI 1584862 No dispute reported 06/30/2026 1220816336
Principal investigator 1 Genentech, Inc. $500.00 08/08/2025 Non-covered Recipient Entity
BAY AREA RETINA ASSOCIATES A MEDICAL GROUP
iAMD Observational Study No dispute reported 06/30/2026 1211577678
Principal investigator 1 Genentech, Inc. $2,400.00 08/05/2025 Non-covered Recipient Entity
BAY AREA RETINA ASSOCIATES A MEDICAL GROUP
A Phase 1 SAD MD in Diabetic Macular Edema No dispute reported 06/30/2026 1211577665
Principal investigator 1 Genentech, Inc. $2,000.00 08/05/2025 Non-covered Recipient Entity
BAY AREA RETINA ASSOCIATES A MEDICAL GROUP
A Phase 1 SAD MD in Diabetic Macular Edema No dispute reported 06/30/2026 1211577681
Principal investigator 1 Genentech, Inc. $11,500.00 08/05/2025 Non-covered Recipient Entity
BAY AREA RETINA ASSOCIATES A MEDICAL GROUP
A Phase 1 SAD MD in Diabetic Macular Edema No dispute reported 06/30/2026 1211577690
Principal investigator 1 Boehringer Ingelheim International GmbH $47.50 08/01/2025 Non-covered Recipient Entity
Bay Area Retina Associates Walnut Creek
A Phase 2 Randomized, double-masked, active-controlled study to evaluate efficacy and safety of two regimens of BI 771716 against pegcetacoplan in patients with geographic atrophy secondary to age-related macular degeneration. No dispute reported 06/30/2026 1220778168
Principal investigator 1 Neurotech Pharmaceuticals, Inc. $610.00 08/01/2025 Non-covered Recipient Entity
Bay Area Retina Associates
NTMT-03C No dispute reported 06/30/2026 1249334351
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $117.78 07/29/2025 Non-covered Recipient Entity
Bay Area Retina Associates Walnut Creek
A Phase 2 Randomized, double-masked, active-controlled study to evaluate efficacy and safety of two regimens of BI 771716 against pegcetacoplan in patients with geographic atrophy secondary to age-related macular degeneration. No dispute reported 06/30/2026 1220816290
Principal investigator 1 Janssen Research & Development, LLC $2,847.00 07/28/2025 Non-covered Recipient Entity
BAY AREA RETINA ASSOCIATES
Long-term Extension Study for Participants with Geographic Atrophy (GA) Secondary to Age-related Macular Degeneration (AMD) in JNJ-81201887 Parent Clinical Studies No dispute reported 06/30/2026 1175437646
Principal investigator 1 Apellis Pharmaceuticals, Inc. $2,338.00 07/23/2025 Non-covered Recipient Entity
Bay Area Retina Associates
A Prospective, Multicenter, Open-Label, Observational Phase 4 Study to Evaluate Real-World Safety, Tolerability, and Treatment Patterns of Pegcetacoplan (Syfovre) in Patients With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1250362568
Principal investigator 1 Apellis Pharmaceuticals, Inc. $692.00 07/23/2025 Non-covered Recipient Entity
Bay Area Retina Associates
A Prospective, Multicenter, Open-Label, Observational Phase 4 Study to Evaluate Real-World Safety, Tolerability, and Treatment Patterns of Pegcetacoplan (Syfovre) in Patients With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1250362570
Principal investigator 1 Apellis Pharmaceuticals, Inc. $692.00 07/23/2025 Non-covered Recipient Entity
Bay Area Retina Associates
A Prospective, Multicenter, Open-Label, Observational Phase 4 Study to Evaluate Real-World Safety, Tolerability, and Treatment Patterns of Pegcetacoplan (Syfovre) in Patients With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1250362572
Principal investigator 1 Apellis Pharmaceuticals, Inc. $692.00 07/23/2025 Non-covered Recipient Entity
Bay Area Retina Associates
A Prospective, Multicenter, Open-Label, Observational Phase 4 Study to Evaluate Real-World Safety, Tolerability, and Treatment Patterns of Pegcetacoplan (Syfovre) in Patients With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1250362574
Principal investigator 1 Apellis Pharmaceuticals, Inc. $692.00 07/23/2025 Non-covered Recipient Entity
Bay Area Retina Associates
A Prospective, Multicenter, Open-Label, Observational Phase 4 Study to Evaluate Real-World Safety, Tolerability, and Treatment Patterns of Pegcetacoplan (Syfovre) in Patients With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1250362576
Principal investigator 1 Apellis Pharmaceuticals, Inc. $692.00 07/23/2025 Non-covered Recipient Entity
Bay Area Retina Associates
A Prospective, Multicenter, Open-Label, Observational Phase 4 Study to Evaluate Real-World Safety, Tolerability, and Treatment Patterns of Pegcetacoplan (Syfovre) in Patients With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1250362578
Principal investigator 1 Genentech, Inc. $6,654.00 07/22/2025 Non-covered Recipient Entity
BAY AREA RETINA ASSOCIATES A MEDICAL GROUP
A Phase 1 SAD MD in Diabetic Macular Edema No dispute reported 06/30/2026 1211577675
Principal investigator 1 Genentech, Inc. $6,286.00 07/18/2025 Non-covered Recipient Entity
BAY AREA RETINA ASSOCIATES A MEDICAL GROUP
iAMD Observational Study No dispute reported 06/30/2026 1211577709
Principal investigator 1 Apellis Pharmaceuticals, Inc. $2,338.00 07/16/2025 Non-covered Recipient Entity
Bay Area Retina Associates
A Prospective, Multicenter, Open-Label, Observational Phase 4 Study to Evaluate Real-World Safety, Tolerability, and Treatment Patterns of Pegcetacoplan (Syfovre) in Patients With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1250362580
Principal investigator 1 Apellis Pharmaceuticals, Inc. $692.00 07/16/2025 Non-covered Recipient Entity
Bay Area Retina Associates
A Prospective, Multicenter, Open-Label, Observational Phase 4 Study to Evaluate Real-World Safety, Tolerability, and Treatment Patterns of Pegcetacoplan (Syfovre) in Patients With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1250362582
Principal investigator 1 Apellis Pharmaceuticals, Inc. $692.00 07/16/2025 Non-covered Recipient Entity
Bay Area Retina Associates
A Prospective, Multicenter, Open-Label, Observational Phase 4 Study to Evaluate Real-World Safety, Tolerability, and Treatment Patterns of Pegcetacoplan (Syfovre) in Patients With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1250362584
Principal investigator 1 Apellis Pharmaceuticals, Inc. $692.00 07/16/2025 Non-covered Recipient Entity
Bay Area Retina Associates
A Prospective, Multicenter, Open-Label, Observational Phase 4 Study to Evaluate Real-World Safety, Tolerability, and Treatment Patterns of Pegcetacoplan (Syfovre) in Patients With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1250362586
Principal investigator 1 Apellis Pharmaceuticals, Inc. $692.00 07/16/2025 Non-covered Recipient Entity
Bay Area Retina Associates
A Prospective, Multicenter, Open-Label, Observational Phase 4 Study to Evaluate Real-World Safety, Tolerability, and Treatment Patterns of Pegcetacoplan (Syfovre) in Patients With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1250362588
Principal investigator 1 Apellis Pharmaceuticals, Inc. $692.00 07/16/2025 Non-covered Recipient Entity
Bay Area Retina Associates
A Prospective, Multicenter, Open-Label, Observational Phase 4 Study to Evaluate Real-World Safety, Tolerability, and Treatment Patterns of Pegcetacoplan (Syfovre) in Patients With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1250362590
Principal investigator 1 Apellis Pharmaceuticals, Inc. $692.00 07/16/2025 Non-covered Recipient Entity
Bay Area Retina Associates
A Prospective, Multicenter, Open-Label, Observational Phase 4 Study to Evaluate Real-World Safety, Tolerability, and Treatment Patterns of Pegcetacoplan (Syfovre) in Patients With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1250362592
Principal investigator 1 Apellis Pharmaceuticals, Inc. $692.00 07/16/2025 Non-covered Recipient Entity
Bay Area Retina Associates
A Prospective, Multicenter, Open-Label, Observational Phase 4 Study to Evaluate Real-World Safety, Tolerability, and Treatment Patterns of Pegcetacoplan (Syfovre) in Patients With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1250362594
Principal investigator 1 Apellis Pharmaceuticals, Inc. $1,510.00 07/16/2025 Non-covered Recipient Entity
Bay Area Retina Associates
A Prospective, Multicenter, Open-Label, Observational Phase 4 Study to Evaluate Real-World Safety, Tolerability, and Treatment Patterns of Pegcetacoplan (Syfovre) in Patients With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1250362596
Principal investigator 1 Apellis Pharmaceuticals, Inc. $1,510.00 07/16/2025 Non-covered Recipient Entity
Bay Area Retina Associates
A Prospective, Multicenter, Open-Label, Observational Phase 4 Study to Evaluate Real-World Safety, Tolerability, and Treatment Patterns of Pegcetacoplan (Syfovre) in Patients With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1250362598
Principal investigator 1 Apellis Pharmaceuticals, Inc. $1,941.00 07/16/2025 Non-covered Recipient Entity
Bay Area Retina Associates
A Prospective, Multicenter, Open-Label, Observational Phase 4 Study to Evaluate Real-World Safety, Tolerability, and Treatment Patterns of Pegcetacoplan (Syfovre) in Patients With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1250362600
Principal investigator 1 Neurotech Pharmaceuticals, Inc. $1,800.00 07/16/2025 Non-covered Recipient Entity
Bay Area Retina Associates
NTMT-03C No dispute reported 06/30/2026 1249334383
Principal investigator 1 Genentech, Inc. $500.00 07/11/2025 Non-covered Recipient Entity
BAY AREA RETINA ASSOCIATES A MEDICAL GROUP
iAMD Observational Study No dispute reported 06/30/2026 1211577661
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $982.00 07/10/2025 Non-covered Recipient Entity
Bay Area Retina Associates Walnut Creek
A Phase 2 Randomized, double-masked, active-controlled study to evaluate efficacy and safety of two regimens of BI 771716 against pegcetacoplan in patients with geographic atrophy secondary to age-related macular degeneration. No dispute reported 06/30/2026 1220816288
Principal investigator 1 Roche TCRC, Inc. $6,629.00 07/07/2025 Non-covered Recipient Entity
Bay Area Retina
ENTRY INTO HUMAN OF RO7497372 IN PARTICIPANTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1211577533
Principal investigator 1 Boehringer Ingelheim International GmbH $47.50 07/01/2025 Non-covered Recipient Entity
Bay Area Retina Associates Walnut Creek
A Phase 2 Randomized, double-masked, active-controlled study to evaluate efficacy and safety of two regimens of BI 771716 against pegcetacoplan in patients with geographic atrophy secondary to age-related macular degeneration. No dispute reported 06/30/2026 1220778166
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $103.49 07/01/2025 Non-covered Recipient Entity
Bay Area Retina Associates Walnut Creek
A Phase 2 Randomized, double-masked, active-controlled study to evaluate efficacy and safety of two regimens of BI 771716 against pegcetacoplan in patients with geographic atrophy secondary to age-related macular degeneration. No dispute reported 06/30/2026 1220816286
Principal investigator 1 Neurotech Pharmaceuticals, Inc. $359.56 07/01/2025 Non-covered Recipient Entity
Bay Area Retina Associates
NTMT-03C No dispute reported 06/30/2026 1249334349
Principal investigator 1 Boehringer Ingelheim International GmbH $159.84 06/24/2025 Non-covered Recipient Entity
Bay Area Retina Associates Walnut Creek
A Phase 2 Randomized, double-masked, active-controlled study to evaluate efficacy and safety of two regimens of BI 771716 against pegcetacoplan in patients with geographic atrophy secondary to age-related macular degeneration. No dispute reported 06/30/2026 1220778156
Principal investigator 1 Boehringer Ingelheim International GmbH $219.00 06/24/2025 Non-covered Recipient Entity
Bay Area Retina Associates Walnut Creek
A Phase 2 Randomized, double-masked, active-controlled study to evaluate efficacy and safety of two regimens of BI 771716 against pegcetacoplan in patients with geographic atrophy secondary to age-related macular degeneration. No dispute reported 06/30/2026 1220778158
Principal investigator 1 Boehringer Ingelheim International GmbH $69.60 06/24/2025 Non-covered Recipient Entity
Bay Area Retina Associates Walnut Creek
A Phase 2 Randomized, double-masked, active-controlled study to evaluate efficacy and safety of two regimens of BI 771716 against pegcetacoplan in patients with geographic atrophy secondary to age-related macular degeneration. No dispute reported 06/30/2026 1220778160
Principal investigator 1 Boehringer Ingelheim International GmbH $12.00 06/24/2025 Non-covered Recipient Entity
Bay Area Retina Associates Walnut Creek
A Phase 2 Randomized, double-masked, active-controlled study to evaluate efficacy and safety of two regimens of BI 771716 against pegcetacoplan in patients with geographic atrophy secondary to age-related macular degeneration. No dispute reported 06/30/2026 1220778162
Principal investigator 1 Boehringer Ingelheim International GmbH $2.44 06/24/2025 Non-covered Recipient Entity
Bay Area Retina Associates Walnut Creek
A Phase 2 Randomized, double-masked, active-controlled study to evaluate efficacy and safety of two regimens of BI 771716 against pegcetacoplan in patients with geographic atrophy secondary to age-related macular degeneration. No dispute reported 06/30/2026 1220778164
Principal investigator 1 Boehringer Ingelheim International GmbH $159.84 06/24/2025 Non-covered Recipient Entity
Bay Area Retina Associates Walnut Creek
JADE: Phase II trial in patients with geographic atrophy: A randomized, double-masked, placebo-controlled, dose-finding study to evaluate the efficacy and safety of BI 1584862 No dispute reported 06/30/2026 1220778196
Principal investigator 1 Boehringer Ingelheim International GmbH $219.00 06/24/2025 Non-covered Recipient Entity
Bay Area Retina Associates Walnut Creek
JADE: Phase II trial in patients with geographic atrophy: A randomized, double-masked, placebo-controlled, dose-finding study to evaluate the efficacy and safety of BI 1584862 No dispute reported 06/30/2026 1220778198
Principal investigator 1 Boehringer Ingelheim International GmbH $6.00 06/24/2025 Non-covered Recipient Entity
Bay Area Retina Associates Walnut Creek
JADE: Phase II trial in patients with geographic atrophy: A randomized, double-masked, placebo-controlled, dose-finding study to evaluate the efficacy and safety of BI 1584862 No dispute reported 06/30/2026 1220778200
Principal investigator 1 Apellis Pharmaceuticals, Inc. $2,004.00 06/20/2025 Non-covered Recipient Entity
Bay Area Retina Associates
A Prospective, Multicenter, Open-Label, Observational Phase 4 Study to Evaluate Real-World Safety, Tolerability, and Treatment Patterns of Pegcetacoplan (Syfovre) in Patients With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1250362636
Principal investigator 1 Apellis Pharmaceuticals, Inc. $2,004.00 06/20/2025 Non-covered Recipient Entity
Bay Area Retina Associates
A Prospective, Multicenter, Open-Label, Observational Phase 4 Study to Evaluate Real-World Safety, Tolerability, and Treatment Patterns of Pegcetacoplan (Syfovre) in Patients With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1250362638
Principal investigator 1 Apellis Pharmaceuticals, Inc. $1,510.00 06/20/2025 Non-covered Recipient Entity
Bay Area Retina Associates
A Prospective, Multicenter, Open-Label, Observational Phase 4 Study to Evaluate Real-World Safety, Tolerability, and Treatment Patterns of Pegcetacoplan (Syfovre) in Patients With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1250362640
Principal investigator 1 Apellis Pharmaceuticals, Inc. $1,510.00 06/20/2025 Non-covered Recipient Entity
Bay Area Retina Associates
A Prospective, Multicenter, Open-Label, Observational Phase 4 Study to Evaluate Real-World Safety, Tolerability, and Treatment Patterns of Pegcetacoplan (Syfovre) in Patients With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1250362642
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $149.96 06/19/2025 Non-covered Recipient Entity
Bay Area Retina Associates Walnut Creek
JADE: Phase II trial in patients with geographic atrophy: A randomized, double-masked, placebo-controlled, dose-finding study to evaluate the efficacy and safety of BI 1584862 No dispute reported 06/30/2026 1220816322
Principal investigator 1 Genentech, Inc. $2,658.00 06/18/2025 Non-covered Recipient Entity
BAY AREA RETINA ASSOCIATES A MEDICAL GROUP
iAMD Observational Study No dispute reported 06/30/2026 1211577652
Recipient Regeneron Pharmaceuticals, Inc. $179.52 06/17/2025 Covered Recipient Physician A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1184117815
Principal investigator 1 Neurotech Pharmaceuticals, Inc. $3,466.00 06/16/2025 Non-covered Recipient Entity
Bay Area Retina Associates
NTMT-03C No dispute reported 06/30/2026 1249334347
Principal investigator 1 Neurotech Pharmaceuticals, Inc. $5,839.20 06/16/2025 Non-covered Recipient Entity
Bay Area Retina Associates
NTMT-03C No dispute reported 06/30/2026 1249334381
Principal investigator 1 Apellis Pharmaceuticals, Inc. $500.00 06/13/2025 Non-covered Recipient Entity
Bay Area Retina Associates
A Prospective, Multicenter, Open-Label, Observational Phase 4 Study to Evaluate Real-World Safety, Tolerability, and Treatment Patterns of Pegcetacoplan (Syfovre) in Patients With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1250362634
Principal investigator 1 Apellis Pharmaceuticals, Inc. $1,000.00 06/11/2025 Non-covered Recipient Entity
Bay Area Retina Associates
Not supplied No dispute reported 06/30/2026 1250362632
Principal investigator 1 Genentech, Inc. $500.00 06/11/2025 Non-covered Recipient Entity
BAY AREA RETINA ASSOCIATES A MEDICAL GROUP
iAMD Observational Study No dispute reported 06/30/2026 1211577627
Principal investigator 1 Genentech, Inc. $84.00 06/11/2025 Non-covered Recipient Entity
BAY AREA RETINA ASSOCIATES A MEDICAL GROUP
iAMD Observational Study No dispute reported 06/30/2026 1211577639
Principal investigator 1 Roche TCRC, Inc. $500.00 06/11/2025 Non-covered Recipient Entity
Bay Area Retina
ENTRY INTO HUMAN OF RO7497372 IN PARTICIPANTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1211577517
Principal investigator 1 Roche TCRC, Inc. $102.15 06/09/2025 Non-covered Recipient Entity
Bay Area Retina
ENTRY INTO HUMAN OF RO7497372 IN PARTICIPANTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1211577525
Principal investigator 1 Roche TCRC, Inc. $294.25 06/05/2025 Non-covered Recipient Entity
Bay Area Retina
ENTRY INTO HUMAN OF RO7497372 IN PARTICIPANTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1211577506
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $79.52 06/04/2025 Non-covered Recipient Entity
Bay Area Retina Associates Walnut Creek
A Phase 2 Randomized, double-masked, active-controlled study to evaluate efficacy and safety of two regimens of BI 771716 against pegcetacoplan in patients with geographic atrophy secondary to age-related macular degeneration. No dispute reported 06/30/2026 1220816282
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $60.00 06/04/2025 Non-covered Recipient Entity
Bay Area Retina Associates Walnut Creek
A Phase 2 Randomized, double-masked, active-controlled study to evaluate efficacy and safety of two regimens of BI 771716 against pegcetacoplan in patients with geographic atrophy secondary to age-related macular degeneration. No dispute reported 06/30/2026 1220816284
Principal investigator 1 Boehringer Ingelheim International GmbH $24.94 06/01/2025 Non-covered Recipient Entity
Bay Area Retina Associates Walnut Creek
A Phase 2 Randomized, double-masked, active-controlled study to evaluate efficacy and safety of two regimens of BI 771716 against pegcetacoplan in patients with geographic atrophy secondary to age-related macular degeneration. No dispute reported 06/30/2026 1220778140
Principal investigator 1 Boehringer Ingelheim International GmbH $43.00 06/01/2025 Non-covered Recipient Entity
Bay Area Retina Associates Walnut Creek
A Phase 2 Randomized, double-masked, active-controlled study to evaluate efficacy and safety of two regimens of BI 771716 against pegcetacoplan in patients with geographic atrophy secondary to age-related macular degeneration. No dispute reported 06/30/2026 1220778142
Principal investigator 1 Boehringer Ingelheim International GmbH $47.50 06/01/2025 Non-covered Recipient Entity
Bay Area Retina Associates Walnut Creek
A Phase 2 Randomized, double-masked, active-controlled study to evaluate efficacy and safety of two regimens of BI 771716 against pegcetacoplan in patients with geographic atrophy secondary to age-related macular degeneration. No dispute reported 06/30/2026 1220778144
Principal investigator 1 Genentech, Inc. $886.00 05/28/2025 Non-covered Recipient Entity
BAY AREA RETINA ASSOCIATES A MEDICAL GROUP
iAMD Observational Study No dispute reported 06/30/2026 1211577635
Principal investigator 1 Boehringer Ingelheim International GmbH $99.90 05/27/2025 Non-covered Recipient Entity
Bay Area Retina Associates Walnut Creek
A Phase 2 Randomized, double-masked, active-controlled study to evaluate efficacy and safety of two regimens of BI 771716 against pegcetacoplan in patients with geographic atrophy secondary to age-related macular degeneration. No dispute reported 06/30/2026 1220778146
Principal investigator 1 Boehringer Ingelheim International GmbH $219.00 05/27/2025 Non-covered Recipient Entity
Bay Area Retina Associates Walnut Creek
A Phase 2 Randomized, double-masked, active-controlled study to evaluate efficacy and safety of two regimens of BI 771716 against pegcetacoplan in patients with geographic atrophy secondary to age-related macular degeneration. No dispute reported 06/30/2026 1220778148
Principal investigator 1 Boehringer Ingelheim International GmbH $55.68 05/27/2025 Non-covered Recipient Entity
Bay Area Retina Associates Walnut Creek
A Phase 2 Randomized, double-masked, active-controlled study to evaluate efficacy and safety of two regimens of BI 771716 against pegcetacoplan in patients with geographic atrophy secondary to age-related macular degeneration. No dispute reported 06/30/2026 1220778150
Principal investigator 1 Boehringer Ingelheim International GmbH $6.00 05/27/2025 Non-covered Recipient Entity
Bay Area Retina Associates Walnut Creek
A Phase 2 Randomized, double-masked, active-controlled study to evaluate efficacy and safety of two regimens of BI 771716 against pegcetacoplan in patients with geographic atrophy secondary to age-related macular degeneration. No dispute reported 06/30/2026 1220778152
Principal investigator 1 Boehringer Ingelheim International GmbH $1.22 05/27/2025 Non-covered Recipient Entity
Bay Area Retina Associates Walnut Creek
A Phase 2 Randomized, double-masked, active-controlled study to evaluate efficacy and safety of two regimens of BI 771716 against pegcetacoplan in patients with geographic atrophy secondary to age-related macular degeneration. No dispute reported 06/30/2026 1220778154
Principal investigator 1 Boehringer Ingelheim International GmbH $259.74 05/27/2025 Non-covered Recipient Entity
Bay Area Retina Associates Walnut Creek
JADE: Phase II trial in patients with geographic atrophy: A randomized, double-masked, placebo-controlled, dose-finding study to evaluate the efficacy and safety of BI 1584862 No dispute reported 06/30/2026 1220778190
Principal investigator 1 Boehringer Ingelheim International GmbH $365.00 05/27/2025 Non-covered Recipient Entity
Bay Area Retina Associates Walnut Creek
JADE: Phase II trial in patients with geographic atrophy: A randomized, double-masked, placebo-controlled, dose-finding study to evaluate the efficacy and safety of BI 1584862 No dispute reported 06/30/2026 1220778192
Principal investigator 1 Boehringer Ingelheim International GmbH $10.00 05/27/2025 Non-covered Recipient Entity
Bay Area Retina Associates Walnut Creek
JADE: Phase II trial in patients with geographic atrophy: A randomized, double-masked, placebo-controlled, dose-finding study to evaluate the efficacy and safety of BI 1584862 No dispute reported 06/30/2026 1220778194
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $8,000.00 05/19/2025 Non-covered Recipient Entity
BAY AREA RETINA ASSOCIATES
A Phase 3 Randomized, Double-Masked, Active-Controlled Study of the Efficacy and Safety of 8 MG Aflibercept in Participants with Macular Edema Following Retinal Vein Occlusion No dispute reported 06/30/2026 1184196695
Principal investigator 1 Apellis Pharmaceuticals, Inc. $1,941.00 05/16/2025 Non-covered Recipient Entity
Bay Area Retina Associates
A Prospective, Multicenter, Open-Label, Observational Phase 4 Study to Evaluate Real-World Safety, Tolerability, and Treatment Patterns of Pegcetacoplan (Syfovre) in Patients With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1250362644
Principal investigator 1 Apellis Pharmaceuticals, Inc. $2,004.00 05/16/2025 Non-covered Recipient Entity
Bay Area Retina Associates
A Prospective, Multicenter, Open-Label, Observational Phase 4 Study to Evaluate Real-World Safety, Tolerability, and Treatment Patterns of Pegcetacoplan (Syfovre) in Patients With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1250362646
Principal investigator 1 Apellis Pharmaceuticals, Inc. $2,004.00 05/16/2025 Non-covered Recipient Entity
Bay Area Retina Associates
A Prospective, Multicenter, Open-Label, Observational Phase 4 Study to Evaluate Real-World Safety, Tolerability, and Treatment Patterns of Pegcetacoplan (Syfovre) in Patients With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1250362648
Principal investigator 1 Apellis Pharmaceuticals, Inc. $2,004.00 05/16/2025 Non-covered Recipient Entity
Bay Area Retina Associates
A Prospective, Multicenter, Open-Label, Observational Phase 4 Study to Evaluate Real-World Safety, Tolerability, and Treatment Patterns of Pegcetacoplan (Syfovre) in Patients With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1250362650
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $71.17 05/15/2025 Non-covered Recipient Entity
Bay Area Retina Associates Walnut Creek
A Phase 2 Randomized, double-masked, active-controlled study to evaluate efficacy and safety of two regimens of BI 771716 against pegcetacoplan in patients with geographic atrophy secondary to age-related macular degeneration. No dispute reported 06/30/2026 1220816280
Principal investigator 1 Apellis Pharmaceuticals, Inc. $1,000.00 05/14/2025 Non-covered Recipient Entity
Bay Area Retina Associates
Not supplied No dispute reported 06/30/2026 1250362630
Principal investigator 1 Roche TCRC, Inc. $4,455.97 05/14/2025 Non-covered Recipient Entity
Bay Area Retina
ENTRY INTO HUMAN OF RO7497372 IN PARTICIPANTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1211577513
Principal investigator 1 Genentech, Inc. $500.00 05/09/2025 Non-covered Recipient Entity
BAY AREA RETINA ASSOCIATES A MEDICAL GROUP
iAMD Observational Study No dispute reported 06/30/2026 1211577644
Principal investigator 1 Roche TCRC, Inc. $500.00 05/07/2025 Non-covered Recipient Entity
Bay Area Retina
ENTRY INTO HUMAN OF RO7497372 IN PARTICIPANTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1211577520
Recipient F. Hoffmann-La Roche AG $310.63 05/06/2025 Covered Recipient Physician VA2 PhIII Yosemite No dispute reported 06/30/2026 1211538665
Principal investigator 1 Boehringer Ingelheim International GmbH $47.50 05/01/2025 Non-covered Recipient Entity
Bay Area Retina Associates Walnut Creek
A Phase 2 Randomized, double-masked, active-controlled study to evaluate efficacy and safety of two regimens of BI 771716 against pegcetacoplan in patients with geographic atrophy secondary to age-related macular degeneration. No dispute reported 06/30/2026 1220778138
Principal investigator 1 Genentech, Inc. $5,664.50 05/01/2025 Non-covered Recipient Entity
BAY AREA RETINA ASSOCIATES A MEDICAL GROUP
iAMD Observational Study No dispute reported 06/30/2026 1211577630
Principal investigator 1 Neurotech Pharmaceuticals, Inc. $8,950.00 05/01/2025 Non-covered Recipient Entity
Bay Area Retina Associates
NTMT-03C No dispute reported 06/30/2026 1249334379
Principal investigator 1 Roche TCRC, Inc. $4,500.00 04/29/2025 Non-covered Recipient Entity
Bay Area Retina
Phase 2 study of Anti IL6 MAb with RBZ in combination in patients with DME No dispute reported 06/30/2026 1211577467
Principal investigator 1 Roche TCRC, Inc. $237.30 04/23/2025 Non-covered Recipient Entity
Bay Area Retina
ENTRY INTO HUMAN OF RO7497372 IN PARTICIPANTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1211577529
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $13,000.00 04/19/2025 Non-covered Recipient Entity
Bay Area Retina Associates Walnut Creek
A Phase 2 Randomized, double-masked, active-controlled study to evaluate efficacy and safety of two regimens of BI 771716 against pegcetacoplan in patients with geographic atrophy secondary to age-related macular degeneration. No dispute reported 06/30/2026 1220816274
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $750.00 04/19/2025 Non-covered Recipient Entity
Bay Area Retina Associates Walnut Creek
A Phase 2 Randomized, double-masked, active-controlled study to evaluate efficacy and safety of two regimens of BI 771716 against pegcetacoplan in patients with geographic atrophy secondary to age-related macular degeneration. No dispute reported 06/30/2026 1220816276
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $750.00 04/19/2025 Non-covered Recipient Entity
Bay Area Retina Associates Walnut Creek
A Phase 2 Randomized, double-masked, active-controlled study to evaluate efficacy and safety of two regimens of BI 771716 against pegcetacoplan in patients with geographic atrophy secondary to age-related macular degeneration. No dispute reported 06/30/2026 1220816278
Principal investigator 1 Apellis Pharmaceuticals, Inc. $13,500.00 04/16/2025 Non-covered Recipient Entity
Bay Area Retina Associates
Not supplied No dispute reported 06/30/2026 1250362626
Principal investigator 1 Apellis Pharmaceuticals, Inc. $1,000.00 04/16/2025 Non-covered Recipient Entity
Bay Area Retina Associates
Not supplied No dispute reported 06/30/2026 1250362628
Principal investigator 1 Genentech, Inc. $500.00 04/16/2025 Non-covered Recipient Entity
BAY AREA RETINA ASSOCIATES A MEDICAL GROUP
iAMD Observational Study No dispute reported 06/30/2026 1211577649
Principal investigator 1 Genentech, Inc. $146.00 04/16/2025 Non-covered Recipient Entity
BAY AREA RETINA ASSOCIATES A MEDICAL GROUP
iAMD Observational Study No dispute reported 06/30/2026 1211577656
Principal investigator 1 Roche TCRC, Inc. $3,650.00 04/11/2025 Non-covered Recipient Entity
Bay Area Retina
A STUDY TO INVESTIGATE RO7200394 AS NOVEL INTRAVITREAL TREATMENT FOR CENTRAL RETINAL VEIN OCCLUSION No dispute reported 06/30/2026 1211577509
Principal investigator 1 Neurotech Pharmaceuticals, Inc. $9,850.00 04/04/2025 Non-covered Recipient Entity
Bay Area Retina Associates
NTMT-03C No dispute reported 06/30/2026 1249334377
Principal investigator 1 Roche TCRC, Inc. $10,648.00 04/03/2025 Non-covered Recipient Entity
Bay Area Retina
ENTRY INTO HUMAN OF RO7497372 IN PARTICIPANTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1211577502
Principal investigator 1 Boehringer Ingelheim International GmbH $43.00 04/01/2025 Non-covered Recipient Entity
Bay Area Retina Associates Walnut Creek
A Phase 2 Randomized, double-masked, active-controlled study to evaluate efficacy and safety of two regimens of BI 771716 against pegcetacoplan in patients with geographic atrophy secondary to age-related macular degeneration. No dispute reported 06/30/2026 1220778132
Principal investigator 1 Boehringer Ingelheim International GmbH $47.50 04/01/2025 Non-covered Recipient Entity
Bay Area Retina Associates Walnut Creek
A Phase 2 Randomized, double-masked, active-controlled study to evaluate efficacy and safety of two regimens of BI 771716 against pegcetacoplan in patients with geographic atrophy secondary to age-related macular degeneration. No dispute reported 06/30/2026 1220778134
Principal investigator 1 Boehringer Ingelheim International GmbH $24.94 04/01/2025 Non-covered Recipient Entity
Bay Area Retina Associates Walnut Creek
A Phase 2 Randomized, double-masked, active-controlled study to evaluate efficacy and safety of two regimens of BI 771716 against pegcetacoplan in patients with geographic atrophy secondary to age-related macular degeneration. No dispute reported 06/30/2026 1220778136
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $59.61 04/01/2025 Non-covered Recipient Entity
Bay Area Retina Associates Walnut Creek
A Phase 2 Randomized, double-masked, active-controlled study to evaluate efficacy and safety of two regimens of BI 771716 against pegcetacoplan in patients with geographic atrophy secondary to age-related macular degeneration. No dispute reported 06/30/2026 1220816272
Recipient F. Hoffmann-La Roche AG $439.58 03/31/2025 Covered Recipient Physician VA2 PhIII Yosemite No dispute reported 06/30/2026 1211538668
Recipient F. Hoffmann-La Roche AG $689.33 03/31/2025 Covered Recipient Physician VA2 PhIII Yosemite No dispute reported 06/30/2026 1211538672
Principal investigator 1 Apellis Pharmaceuticals, Inc. $1,000.00 03/26/2025 Non-covered Recipient Entity
Bay Area Retina Associates
Not supplied No dispute reported 06/30/2026 1250362666
Principal investigator 1 Boehringer Ingelheim International GmbH $151.58 03/25/2025 Non-covered Recipient Entity
Bay Area Retina Associates Walnut Creek
A Phase 2 Randomized, double-masked, active-controlled study to evaluate efficacy and safety of two regimens of BI 771716 against pegcetacoplan in patients with geographic atrophy secondary to age-related macular degeneration. No dispute reported 06/30/2026 1220778116
Principal investigator 1 Boehringer Ingelheim International GmbH $279.72 03/25/2025 Non-covered Recipient Entity
Bay Area Retina Associates Walnut Creek
A Phase 2 Randomized, double-masked, active-controlled study to evaluate efficacy and safety of two regimens of BI 771716 against pegcetacoplan in patients with geographic atrophy secondary to age-related macular degeneration. No dispute reported 06/30/2026 1220778118
Principal investigator 1 Boehringer Ingelheim International GmbH $876.00 03/25/2025 Non-covered Recipient Entity
Bay Area Retina Associates Walnut Creek
A Phase 2 Randomized, double-masked, active-controlled study to evaluate efficacy and safety of two regimens of BI 771716 against pegcetacoplan in patients with geographic atrophy secondary to age-related macular degeneration. No dispute reported 06/30/2026 1220778120
Principal investigator 1 Boehringer Ingelheim International GmbH $218.08 03/25/2025 Non-covered Recipient Entity
Bay Area Retina Associates Walnut Creek
A Phase 2 Randomized, double-masked, active-controlled study to evaluate efficacy and safety of two regimens of BI 771716 against pegcetacoplan in patients with geographic atrophy secondary to age-related macular degeneration. No dispute reported 06/30/2026 1220778122
Principal investigator 1 Boehringer Ingelheim International GmbH $7.44 03/25/2025 Non-covered Recipient Entity
Bay Area Retina Associates Walnut Creek
A Phase 2 Randomized, double-masked, active-controlled study to evaluate efficacy and safety of two regimens of BI 771716 against pegcetacoplan in patients with geographic atrophy secondary to age-related macular degeneration. No dispute reported 06/30/2026 1220778124
Principal investigator 1 Boehringer Ingelheim International GmbH $18.00 03/25/2025 Non-covered Recipient Entity
Bay Area Retina Associates Walnut Creek
A Phase 2 Randomized, double-masked, active-controlled study to evaluate efficacy and safety of two regimens of BI 771716 against pegcetacoplan in patients with geographic atrophy secondary to age-related macular degeneration. No dispute reported 06/30/2026 1220778126
Principal investigator 1 Boehringer Ingelheim International GmbH $3.66 03/25/2025 Non-covered Recipient Entity
Bay Area Retina Associates Walnut Creek
A Phase 2 Randomized, double-masked, active-controlled study to evaluate efficacy and safety of two regimens of BI 771716 against pegcetacoplan in patients with geographic atrophy secondary to age-related macular degeneration. No dispute reported 06/30/2026 1220778128
Principal investigator 1 Boehringer Ingelheim International GmbH $69.96 03/25/2025 Non-covered Recipient Entity
Bay Area Retina Associates Walnut Creek
JADE: Phase II trial in patients with geographic atrophy: A randomized, double-masked, placebo-controlled, dose-finding study to evaluate the efficacy and safety of BI 1584862 No dispute reported 06/30/2026 1220778182
Principal investigator 1 Boehringer Ingelheim International GmbH $319.68 03/25/2025 Non-covered Recipient Entity
Bay Area Retina Associates Walnut Creek
JADE: Phase II trial in patients with geographic atrophy: A randomized, double-masked, placebo-controlled, dose-finding study to evaluate the efficacy and safety of BI 1584862 No dispute reported 06/30/2026 1220778184
Principal investigator 1 Boehringer Ingelheim International GmbH $328.50 03/25/2025 Non-covered Recipient Entity
Bay Area Retina Associates Walnut Creek
JADE: Phase II trial in patients with geographic atrophy: A randomized, double-masked, placebo-controlled, dose-finding study to evaluate the efficacy and safety of BI 1584862 No dispute reported 06/30/2026 1220778186
Principal investigator 1 Boehringer Ingelheim International GmbH $7.00 03/25/2025 Non-covered Recipient Entity
Bay Area Retina Associates Walnut Creek
JADE: Phase II trial in patients with geographic atrophy: A randomized, double-masked, placebo-controlled, dose-finding study to evaluate the efficacy and safety of BI 1584862 No dispute reported 06/30/2026 1220778188
Principal investigator 1 Genentech, Inc. $500.00 03/21/2025 Non-covered Recipient Entity
BAY AREA RETINA ASSOCIATES A MEDICAL GROUP
iAMD Observational Study No dispute reported 06/30/2026 1211577589
Principal investigator 1 Apellis Pharmaceuticals, Inc. $2,338.00 03/14/2025 Non-covered Recipient Entity
Bay Area Retina Associates
A Prospective, Multicenter, Open-Label, Observational Phase 4 Study to Evaluate Real-World Safety, Tolerability, and Treatment Patterns of Pegcetacoplan (Syfovre) in Patients With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1250362612
Principal investigator 1 Apellis Pharmaceuticals, Inc. $1,510.00 03/14/2025 Non-covered Recipient Entity
Bay Area Retina Associates
A Prospective, Multicenter, Open-Label, Observational Phase 4 Study to Evaluate Real-World Safety, Tolerability, and Treatment Patterns of Pegcetacoplan (Syfovre) in Patients With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1250362614
Principal investigator 1 Genentech, Inc. $2,658.00 03/14/2025 Non-covered Recipient Entity
BAY AREA RETINA ASSOCIATES A MEDICAL GROUP
iAMD Observational Study No dispute reported 06/30/2026 1211577593
Principal investigator 1 Genentech, Inc. $124.00 03/14/2025 Non-covered Recipient Entity
BAY AREA RETINA ASSOCIATES A MEDICAL GROUP
iAMD Observational Study No dispute reported 06/30/2026 1211577619
Principal investigator 1 Janssen Research & Development, LLC $48.00 03/14/2025 Non-covered Recipient Entity
BAY AREA RETINA ASSOCIATES
Long-term Extension Study for Participants with Geographic Atrophy (GA) Secondary to Age-related Macular Degeneration (AMD) in JNJ-81201887 Parent Clinical Studies No dispute reported 06/30/2026 1175437655
Principal investigator 1 Apellis Pharmaceuticals, Inc. $210.00 03/05/2025 Non-covered Recipient Entity
Bay Area Retina Associates
A Prospective, Multicenter, Open-Label, Observational Phase 4 Study to Evaluate Real-World Safety, Tolerability, and Treatment Patterns of Pegcetacoplan (Syfovre) in Patients With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1250362606
Principal investigator 1 Boehringer Ingelheim International GmbH $47.50 03/01/2025 Non-covered Recipient Entity
Bay Area Retina Associates Walnut Creek
A Phase 2 Randomized, double-masked, active-controlled study to evaluate efficacy and safety of two regimens of BI 771716 against pegcetacoplan in patients with geographic atrophy secondary to age-related macular degeneration. No dispute reported 06/30/2026 1220778112
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $40.48 03/01/2025 Non-covered Recipient Entity
Bay Area Retina Associates Walnut Creek
A Phase 2 Randomized, double-masked, active-controlled study to evaluate efficacy and safety of two regimens of BI 771716 against pegcetacoplan in patients with geographic atrophy secondary to age-related macular degeneration. No dispute reported 06/30/2026 1220816270
Principal investigator 1 Roche TCRC, Inc. $315.84 02/28/2025 Non-covered Recipient Entity
Bay Area Retina
ENTRY INTO HUMAN OF RO7497372 IN PARTICIPANTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1211577495
Principal investigator 1 Genentech, Inc. $1,772.00 02/26/2025 Non-covered Recipient Entity
BAY AREA RETINA ASSOCIATES A MEDICAL GROUP
iAMD Observational Study No dispute reported 06/30/2026 1211577584
Principal investigator 1 Genentech, Inc. $2,418.00 02/26/2025 Non-covered Recipient Entity
BAY AREA RETINA ASSOCIATES A MEDICAL GROUP
iAMD Observational Study No dispute reported 06/30/2026 1211577595
Principal investigator 1 Genentech, Inc. $981.00 02/26/2025 Non-covered Recipient Entity
BAY AREA RETINA ASSOCIATES A MEDICAL GROUP
iAMD Observational Study No dispute reported 06/30/2026 1211577598
Principal investigator 1 Boehringer Ingelheim International GmbH $79.92 02/25/2025 Non-covered Recipient Entity
Bay Area Retina Associates Walnut Creek
A Phase 2 Randomized, double-masked, active-controlled study to evaluate efficacy and safety of two regimens of BI 771716 against pegcetacoplan in patients with geographic atrophy secondary to age-related macular degeneration. No dispute reported 06/30/2026 1220778114
Principal investigator 1 Apellis Pharmaceuticals, Inc. $2,338.00 02/19/2025 Non-covered Recipient Entity
Bay Area Retina Associates
A Prospective, Multicenter, Open-Label, Observational Phase 4 Study to Evaluate Real-World Safety, Tolerability, and Treatment Patterns of Pegcetacoplan (Syfovre) in Patients With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1250362602
Principal investigator 1 Apellis Pharmaceuticals, Inc. $1,510.00 02/19/2025 Non-covered Recipient Entity
Bay Area Retina Associates
A Prospective, Multicenter, Open-Label, Observational Phase 4 Study to Evaluate Real-World Safety, Tolerability, and Treatment Patterns of Pegcetacoplan (Syfovre) in Patients With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1250362604
Principal investigator 1 Genentech, Inc. $17.35 02/19/2025 Non-covered Recipient Entity
BAY AREA RETINA ASSOCIATES A MEDICAL GROUP
iAMD Observational Study No dispute reported 06/30/2026 1211577602
Principal investigator 1 Genentech, Inc. $500.00 02/19/2025 Non-covered Recipient Entity
BAY AREA RETINA ASSOCIATES A MEDICAL GROUP
iAMD Observational Study No dispute reported 06/30/2026 1211577623
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $239.05 02/12/2025 Non-covered Recipient Entity
Bay Area Retina Associates Walnut Creek
A Phase 2 Randomized, double-masked, active-controlled study to evaluate efficacy and safety of two regimens of BI 771716 against pegcetacoplan in patients with geographic atrophy secondary to age-related macular degeneration. No dispute reported 06/30/2026 1220816268
Principal investigator 1 Roche TCRC, Inc. $252.00 02/11/2025 Non-covered Recipient Entity
Bay Area Retina
ENTRY INTO HUMAN OF RO7497372 IN PARTICIPANTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1211577479
Principal investigator 1 Roche TCRC, Inc. $575.43 02/11/2025 Non-covered Recipient Entity
Bay Area Retina
ENTRY INTO HUMAN OF RO7497372 IN PARTICIPANTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1211577498
Principal investigator 1 Boehringer Ingelheim International GmbH $47.50 02/01/2025 Non-covered Recipient Entity
Bay Area Retina Associates Walnut Creek
A Phase 2 Randomized, double-masked, active-controlled study to evaluate efficacy and safety of two regimens of BI 771716 against pegcetacoplan in patients with geographic atrophy secondary to age-related macular degeneration. No dispute reported 06/30/2026 1220778110
Principal investigator 1 Boehringer Ingelheim International GmbH $78.39 01/31/2025 Non-covered Recipient Entity
Bay Area Retina Associates Walnut Creek
BI 771716 - SRD and MD in geographic atrophy patients No dispute reported 06/30/2026 1220778108
Principal investigator 1 Roche TCRC, Inc. $500.00 01/27/2025 Non-covered Recipient Entity
Bay Area Retina
ENTRY INTO HUMAN OF RO7497372 IN PARTICIPANTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1211577492
Principal investigator 1 Apellis Pharmaceuticals, Inc. $1,510.00 01/24/2025 Non-covered Recipient Entity
Bay Area Retina Associates
A Prospective, Multicenter, Open-Label, Observational Phase 4 Study to Evaluate Real-World Safety, Tolerability, and Treatment Patterns of Pegcetacoplan (Syfovre) in Patients With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1250362616
Principal investigator 1 Apellis Pharmaceuticals, Inc. $2,004.00 01/24/2025 Non-covered Recipient Entity
Bay Area Retina Associates
A Prospective, Multicenter, Open-Label, Observational Phase 4 Study to Evaluate Real-World Safety, Tolerability, and Treatment Patterns of Pegcetacoplan (Syfovre) in Patients With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1250362618
Principal investigator 1 Apellis Pharmaceuticals, Inc. $2,004.00 01/24/2025 Non-covered Recipient Entity
Bay Area Retina Associates
A Prospective, Multicenter, Open-Label, Observational Phase 4 Study to Evaluate Real-World Safety, Tolerability, and Treatment Patterns of Pegcetacoplan (Syfovre) in Patients With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1250362620
Principal investigator 1 Apellis Pharmaceuticals, Inc. $2,004.00 01/24/2025 Non-covered Recipient Entity
Bay Area Retina Associates
A Prospective, Multicenter, Open-Label, Observational Phase 4 Study to Evaluate Real-World Safety, Tolerability, and Treatment Patterns of Pegcetacoplan (Syfovre) in Patients With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1250362622
Principal investigator 1 Apellis Pharmaceuticals, Inc. $2,004.00 01/24/2025 Non-covered Recipient Entity
Bay Area Retina Associates
A Prospective, Multicenter, Open-Label, Observational Phase 4 Study to Evaluate Real-World Safety, Tolerability, and Treatment Patterns of Pegcetacoplan (Syfovre) in Patients With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1250362624
Principal investigator 1 Genentech, Inc. $6,675.00 01/22/2025 Non-covered Recipient Entity
BAY AREA RETINA ASSOCIATES A MEDICAL GROUP
iAMD Observational Study No dispute reported 06/30/2026 1211577580
Principal investigator 1 Roche TCRC, Inc. $3,941.00 01/21/2025 Non-covered Recipient Entity
Bay Area Retina
PHASE 2 STUDY TO INVESTIGATE RO7200220 IN DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1211577464
Principal investigator 1 Genentech, Inc. $104.00 01/17/2025 Non-covered Recipient Entity
BAY AREA RETINA ASSOCIATES A MEDICAL GROUP
iAMD Observational Study No dispute reported 06/30/2026 1211577607
Principal investigator 1 Genentech, Inc. $37.74 01/17/2025 Non-covered Recipient Entity
BAY AREA RETINA ASSOCIATES A MEDICAL GROUP
iAMD Observational Study No dispute reported 06/30/2026 1211577615
Principal investigator 1 Apellis Pharmaceuticals, Inc. $2,120.00 01/15/2025 Non-covered Recipient Entity
Bay Area Retina Associates
A Prospective, Multicenter, Open-Label, Observational Phase 4 Study to Evaluate Real-World Safety, Tolerability, and Treatment Patterns of Pegcetacoplan (Syfovre) in Patients With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1250362608
Principal investigator 1 Apellis Pharmaceuticals, Inc. $348.00 01/15/2025 Non-covered Recipient Entity
Bay Area Retina Associates
A Prospective, Multicenter, Open-Label, Observational Phase 4 Study to Evaluate Real-World Safety, Tolerability, and Treatment Patterns of Pegcetacoplan (Syfovre) in Patients With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1250362610
Principal investigator 1 Genentech, Inc. $500.00 01/15/2025 Non-covered Recipient Entity
BAY AREA RETINA ASSOCIATES A MEDICAL GROUP
iAMD Observational Study No dispute reported 06/30/2026 1211577610
Principal investigator 1 Roche TCRC, Inc. $1,321.60 01/15/2025 Non-covered Recipient Entity
Bay Area Retina
ENTRY INTO HUMAN OF RO7497372 IN PARTICIPANTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1211577471
Principal investigator 1 Roche TCRC, Inc. $244.43 01/13/2025 Non-covered Recipient Entity
Bay Area Retina
ENTRY INTO HUMAN OF RO7497372 IN PARTICIPANTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1211577484
Principal investigator 1 Roche TCRC, Inc. $1,764.00 01/10/2025 Non-covered Recipient Entity
Bay Area Retina
A STUDY TO INVESTIGATE RO7200394 AS NOVEL INTRAVITREAL TREATMENT FOR CENTRAL RETINAL VEIN OCCLUSION No dispute reported 06/30/2026 1211577475
Principal investigator 1 Janssen Research & Development, LLC $24.00 01/09/2025 Non-covered Recipient Entity
BAY AREA RETINA ASSOCIATES
A Phase 2/3, Randomized, Double-masked, Multicenter, Dose-ranging, Sham-controlled Clinical Trial to Evaluate Intravitreal JNJ-81201887 (AAVCAGsCD59) Compared to Sham Procedure for the Treatment of Geographic Atrophy (GA) Secondary to Age-related Macular No dispute reported 06/30/2026 1175437661
Principal investigator 1 Roche TCRC, Inc. $23,981.00 01/07/2025 Non-covered Recipient Entity
Bay Area Retina
ENTRY INTO HUMAN OF RO7497372 IN PARTICIPANTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1211577488
Principal investigator 1 Boehringer Ingelheim International GmbH $47.50 01/01/2025 Non-covered Recipient Entity
Bay Area Retina Associates Walnut Creek
A Phase 2 Randomized, double-masked, active-controlled study to evaluate efficacy and safety of two regimens of BI 771716 against pegcetacoplan in patients with geographic atrophy secondary to age-related macular degeneration. No dispute reported 06/30/2026 1220778130

Ownership and Investment Interests

One row per program year and measure, newest year first · the amount invested and the value of the interest are never added together

Program yearMeasureAmountRecords
PY2025 Amount invested $1,900.00 1
PY2025 Value of interest $0.00 1

Ownership and Investment Interests are a separate CMS dataset, shown here separately and never added to payments.

Ownership and investment interests are reported as the value of an interest held, not as a payment received. They are a different measure from the payment total on this page and are never combined with it.

Ownership and Investment Interests records

Ordering applied by this site (program year, newest first, then company) · record values are shown as CMS published them

1 record · PY2025

Ownership and Investment Interests records (CSV)

Program yearCompanyAmount invested Value of interestTerms of interestInterest held by Dispute statusPublishedRecord ID
PY2025 Avirmax Biopharma, Inc $1,900.00 $0.00 This option grant shall be subject to the terms and conditions of the Avirmaxs Stock Option Plan and Stock Option Agreement, including vesting requirements. Physician Covered Recipient No dispute reported 06/30/2026 1225318785